6-乙酰氨基吡啶羧酸 | 26893-72-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-乙酰氨基吡啶羧酸
• 中文别名: 6-乙酰氨基吡啶-2-羧酸
• 英文名称: 6-acetamido-picolinic acid
• 英文别名: N-acetyl-6-amino-pyridine-2-carboxylic acid；6-(acetylamino)-2-pyridinecarboxylic acid；6-acetylaminopyridine-2-carboxylic acid；N-acetyl-6-aminopicolinic acid；6-acetylamino picolinic acid；6-Acetamidopicolinic acid；6-acetamidopyridine-2-carboxylic acid
• CAS: 26893-72-1
• 化学式: C₈H₈N₂O₃
• mdl: MFCD00233707
• 分子量: 180.163
• InChiKey: LOMWKYHCHCZVCC-UHFFFAOYSA-N

物化性质

• 熔点：
  227-229 °C(Solv: ethanol (64-17-5))
• 沸点：
  489.0±30.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Acetamidopicolinic acid
Synonyms: 6-Acetylamino-2-pyridinecarboxylic acid; 6-acetamidopyridine-2-carboxylic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Acetamidopicolinic acid
CAS number: 26893-72-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8N2O3
Molecular weight: 180.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-乙酰氨基吡啶羧酸 在 盐酸 、 溴 作用下， 以 氯仿 为溶剂， 反应 58.0h， 生成 6-氨基-3-溴吡啶甲酸甲酯
  参考文献：
  名称：

  GAMMA SECRETASE MODULATORS

  摘要：

  该发明涉及以下式的化合物 其中R 1 ，R 1′ ，R 2 ，R 3 ，n，A和hetaryl在此处定义，或其药用活性酸盐。式I的这些化合物是淀粉样蛋白β的调节剂，因此它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病，遗传性脑出血伴有淀粉样变性，荷兰型（HCHWA-D），多梗死性痴呆，拳击性痴呆和唐氏综合征。

  公开号：

  US20110190269A1
• 作为产物：
  描述：

  6-(acetylamino)-2-methylpyridinium acetate 在 sodium hydroxide 、 potassium permanganate 作用下， 反应 0.5h， 以32%的产率得到6-乙酰氨基吡啶羧酸
  参考文献：
  名称：

  2-（胍基碘羰基）吡啶在水性溶剂中的氨基酸结合：一种比较复杂的结合研究，将复杂的稳定性与立体电子因子相关联。

  摘要：

  已合成了一系列胍基碘羰基吡啶受体，这些化合物结合DMSO水溶液中的氨基酸（羧酸盐形式），其缔合常数范围为K = 30至460 M（-1），这是通过NMR滴定实验确定的。借助计算出的复杂结构，可以将复杂稳定性的差异与空间效应和静电效应相关联。例如，吡啶氮孤对和结合的羧酸根之间的静电排斥使阴离子结合的效率比我们先前引入的用于水中羧酸根结合的类似吡咯受体的效率低。此外，如2b中的受体侧链与结合的底物之间的空间相互作用也不利于络合。

  DOI：

  10.1002/chem.200400652
• 作为试剂：
  描述：

  6-(acetylamino)-2-methylpyridinium acetate 、 sodium hydroxide 在 6-乙酰氨基吡啶羧酸 、 碳酸氢钠 、 乙酸乙酯 、 水 、 氯化钠 、 magnesium sulfate 、 potassium permanganate 、 氯仿 、 盐酸 、 ice water 作用下， 反应 56.5h， 以to obtain the title compound (11.9 g)的产率得到6-乙酰氨基吡啶羧酸
  参考文献：
  名称：

  Benzisoxazole Compound

  摘要：

  本发明涉及一种由通式（I）表示的化合物或其盐：其中R1、R2和R3中的任意一个表示公式表示的基团：—（CH2）m-NR11R12（其中m为1或2；R11和R12独立地表示氢原子或C1-6烷基或可能与R11和R12结合的氮原子一起形成4-或5-成员环状基团）；剩余的两个或R1、R2和R3独立地表示公式表示的基团：—（O）n-R21（其中n为0或1；R21表示氢原子、C1-6烷基、C2-6烯基、C2-6炔基等）；R4表示可能具有取代基的C1-6烷基。

  公开号：

  US20090318690A1

文献信息

• [EN] GAMMA SECRETASE MODULATERS<br/>[FR] MODULATEURS DE GAMMA-SECRÉTASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011092272A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of formula ( I ) wherein R1/R1' are independently from each other hydrogen, halogen, lower alkoxy or cyano; R2 is lower alkyl, halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by OR, =0, -C(O)O-lower alkyl, -C(O)NH-lower alkyl, cyano, CH2-O-lower alkyl, cycloalkyl, NRR'or is -O-(CH2)o-phenyl optionally substituted by halogen, or is -(CH2)o-phenyl optionally substituted by one, two or three substituents, selected from halogen, -(CH2)o-cyano, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, C(O)H, -CH2-NH2-, -CH2-NH-C(O)O-lower alkyl, -CH2-NH-C(O)-lower alkyl, -CH2-NH-lower alkyl, -CH2-NH-S(O)2-lower alkyl, lower alkoxy or by lower alkoxy substituted by halogen, or is -(CH2)o-cycloalkyl, or is -(CH2)o-heterocycloalkyl which is optionally substituted by halogen, CF3, lower alkyl, -CH2CN, -C(O)-lower alkyl, -C(O)O-lower alkyl or S(O)2-lower alkyl, or is heteroaryl selected from the group consisting of furanyl, pyrazinyl, pyridinyl, benzooxazolyl or benzoimidazolyl which are optionally substituted by lower alkyl, or is 4-methyl-3,4-dihydro-2H-benzo[l,4]oxazine R and R' are independently from each other hydrogen or lower alkyl, and o is 0 or 1; R3 may occur once or twice and is lower alkyl; A is Formula a), b), c), d), e), f), h), i), j) and Formula k); R2' is hydrogen, lower alkyl, lower alkyl substituted by halogen, C(O)-lower alkyl, S(O)2-lower alkyl or phenyl optionally substituted by halogen; hetaryl is a 5 or 6 membered N, S or O-containing heteroaryl group; n is O, 1, 2 or 3; if n is 2 or 3, R2 may be the same or not; or to pharmaceutically active acid addition salts thereof. The present compounds of formula ( I ) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi- infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式（I）的化合物，其中R1/R1'分别独立地为氢、卤素、较低的烷氧基或氰基；R2为较低的烷基、卤素、较低的烷氧基、卤素取代的较低烷基、卤素取代的较低烷氧基、取代的较低烷基OR、=0、-C(O)O-较低烷基、-C(O)NH-较低烷基、氰基、CH2-O-较低烷基、环烷基、NRR'或为-O-(CH2)o-苯基，可选择地取代为卤素，或为-(CH2)o-苯基，可选择地取代为一个、两个或三个取代基，选自卤素、-(CH2)o-氰基、较低烷基、卤素取代的较低烷基、羟基取代的较低烷基、C(O)H、-CH2-NH2-、-CH2-NH-C(O)O-较低烷基、-CH2-NH-C(O)-较低烷基、-CH2-NH-较低烷基、-CH2-NH-S(O)2-较低烷基、较低烷氧基或取代的较低烷氧基，或为-(CH2)o-环烷基，或为-(CH2)o-杂环烷基，可选择地取代为卤素、CF3、较低烷基、-CH2CN、-C(O)-较低烷基、-C(O)O-较低烷基或S(O)2-较低烷基，或为杂芳基，选自呋喃基、吡嗪基、吡啶基、苯并噁唑基或苯并咪唑基，可选择地取代为较低烷基，或为4-甲基-3,4-二氢-2H-苯并[l,4]噁啉，R和R'分别独立地为氢或较低烷基，o为0或1；R3可能出现一次或两次，为较低烷基；A为式a)、b)、c)、d)、e)、f)、h)、i)、j)和式k)；R2'为氢、较低烷基、卤素取代的较低烷基、C(O)-较低烷基、S(O)2-较低烷基或可选择地取代为卤素的苯基；hetaryl为5或6成员的含氮、硫或氧的杂芳基；n为O、1、2或3；如果n为2或3，R2可能相同也可能不同；或其药用活性酸盐。该式（I）的化合物是淀粉样蛋白β的调节剂，因此，它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、遗传性淀粉样脑出血症，荷兰型（HCHWA-D），多梗死性痴呆、拳击性痴呆和唐氏综合征。
• Heterocyclic glycyl &bgr;-alanine derivatives
  申请人：G. D. Searle & Co.

  公开号：US06689754B1

  公开（公告）日：2004-02-10

  The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and methods of treating conditions mediated by the &agr;v&bgr;3 integrin.

  本发明涉及一类由化学式I表示的化合物，或其药学上可接受的盐，包含这类化合物的药物组合物以及治疗由αvβ3整合素介导的疾病的方法。
• HETEROARYL SUBSTITUTED PIPERIDINES
  申请人：Baumann Karlheinz

  公开号：US20110201605A1

  公开（公告）日：2011-08-18

  The invention relates to compounds of formula where hetaryl I, hetaryl II, R 1 , R 2 , R 3 , R 4 , m, n, and o are as defined in the specification or to pharmaceutically active acid addition salts thereof. The compounds of formula I are modulators for amyloid beta and thus may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式的化合物 其中hetaryl I，hetaryl II， R 1 ， R 2 ， R 3 ，R 4 ，m，n和o如规范中所定义 或其药用活性酸盐。式I的化合物是淀粉样蛋白β的调节剂，因此可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病，遗传性脑出血伴淀粉样变性，荷兰型（HCHWA-D），多梗塞性痴呆，拳击性痴呆和唐氏综合征。
• [EN] NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY<br/>[FR] NOUVEAUX COMPOSES PRESENTANT UNE ACTIVITE ANTIBACTERIENNE
  申请人：CHEMIE MORPHOCHEM AG FUER KOMB

  公开号：WO2006021448A1

  公开（公告）日：2006-03-02

  The present invention describes novel anti-bacterial compounds of formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase.

  本发明描述了具有通式(I)的新型抗菌化合物。这些化合物在其他方面，尤其是作为DNA促旋酶抑制剂，具有研究价值。
• SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS
  申请人：Svenstrup Niels

  公开号：US20090176842A1

  公开（公告）日：2009-07-09

  The invention relates to substituted arylsulfonamides of formula (I) and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.

  这项发明涉及公式（I）的取代芳基磺酰胺及其制备方法，以及它们用于生产用于治疗和/或预防疾病的药物，特别是用作抗病毒剂，特别是对巨细胞病毒的用途。